New data show that wearable neuromodulation can be used with CGMs without disrupting glucose accuracy or connectivity.

Three of the top diabetes tech companies put forward new clinical data this week, making the case for their continuous glucose monitors and insulin pumps as they look to expand their reac | Three ...

Dexcom (Nasdaq:DXCM) today announced its plans to share new data supporting its diabetes management technology at ATTD 2026.

(NASDAQ:DXCM), the global leader in glucose biosensing, will present new findings that showcase the benefits of its glucose biosensing technology for people with all types of diabetes and share more ...

BTIG analysts continue to expect growth from Dexcom (Nasdaq:DXCM) after meeting with the company's senior investor relations (IR) officials.

Dexcom will stop producing G6 CGM sensors July 1, 2026, urging patients to switch to the smaller, more accurate G7 model.